Dr Reddy’s Q3 results!

Last updated: 29 Jan, 2021 | 07:33 am

Dr Reddy’s Q3 results!

Profit impacted due to impairment charges: Dr Reddy’s has reported a net profit of ₹19.8 crore in Q3FY21, sharply below street estimates as the bottomline was impacted due to impairment charges. Analysts had estimated a profit of about ₹700 crore.  The company’s bottomline in the quarter was adversely affected by a one-time impairment charge of Rs. 592.6 crore with respect to certain products.

Exceptional items drag:  The profits were impacted due to trigger based impairment charge taken on a few acquired products including gNuvaring. Excluding the impairment charge, the Profit before Tax stood at Rs 882 crore.  

Revenue in-line: The company’s consolidated revenues grew 12% YoY to Rs. 4,930 crore, which was largely in-line with street estimate of Rs. 4,975 crore. The gross margin stood at 53.8% against 54.1% in the previous year.

Strong growth in Europe & India: Sales rose in Europe (up 34% YoY to ₹410 crore) and India ( up 26% YoY to ₹960 crore).  North America witnessed a growth of 9 percent YoY while emerging markets grew 5 percent YoY during the December quarter.

While the company has nearly met estimates on the top line, the bottom line has come in below estimates. Competitor Launching a generic version of the product in DRL’s product segment, decrease in the market potential due to higher than expected price erosion have led to the impairment. The company said that it is progressing well on the phase-3 clinical trials for Sputnik V vaccine in India. DRL shares were trading 3.5% lower at ₹4,705 on BSE.

Finzoom Investment Advisors Private Limited (Brand Name - INDmoney, INDwealth, IND.app, IND.money, INDsave.com) makes no warranties or representations, express or implied, on products and services offered through the platform. It accepts no liability for any damages or losses, however, caused in connection with the use of, or on the reliance of its advisory or related services.

Past performance is not indicative of future returns. Please consider your specific investment requirements, risk tolerance, goal, time frame, risk and reward balance and the cost associated with the investment before choosing a fund, or designing a portfolio that suits your needs. Performance and returns of any investment portfolio can neither be predicted nor guaranteed.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Marketing and distribution of various financial products such as loans and deposits are powered by Finzoomers Services Private Limited.

INDmoney, INDwealth, IND.app are brand and product of Finzoom Investment Advisors (P) Limited.

© Finzoom Investment Advisors Private Limited

[SEBI RIA Registration No: INA100012190] [Type of Registration: Non-Individual] [Validity of registration: December 17, 2018-Perpetual] [Address: 616, 6th Floor, Suncity Success Tower, Golf Course Extension Road, Sector – 65, Gurugram, Haryana- 122005] [Principal Officer details: Mr. Gaurav Sharma, Email id: principalofficer@indwealth.in, Contact No. 8800826254] [Corresponding SEBI local office address: Securities and Exchange Board of India, Local Office, First Floor, SCO 127-128, Sector 17C, Chandigarh-160017]

[ARN - 151913] [Platform Partner : BSE (Member code-24801)] [CIN - U67190HR2018PTC073294] [GST No : 06AADCF3538Q1Z8]